Artificial intelligence is increasingly influential in medicine, with new breakthroughs emerging beyond the usual hopes of curing cancer. A promising development comes from Insilico Medicine, an AI-driven company that designed a drug called rentosertib. This drug has demonstrated the potential to reverse biological aging in early clinical trials. Using advanced AI-based “aging clocks,” researchers measured participants’ biological ages before and after a 12-week trial. All 42 participants who took rentosertib showed signs of decreased biological age, while those on placebo did not. Despite these encouraging results, aging clocks remain debated among scientists, and the small sample size—limited to patients with idiopathic pulmonary fibrosis—means further testing is needed. The drug is still far from regulatory approval, but if successful, it could transform the aging process itself.
Back
